Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.73 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628781 | 0.90 | TRPM8 (0.74) | TRPM8TRPV1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14564501 | 0.89 | TRPM8 (0.73) | TRPM8TRPV1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5442957 | 0.89 | TRPM8 (0.73) | TRPM8TRPV1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14564499 | 0.88 | TRPM8 (0.71) | TRPM8TRPV1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10193802 | 0.88 | TRPM8 (0.74) | TRPM8TRPV1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL891210 | 0.88 | TRPM8 (0.74) | TRPM8TRPV1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2628678 | 0.86 | TRPM8 (0.57) | TRPM8MEN1KMT2ARAB9AEPHX1 | |
| SCHEMBL4817987 | 0.86 | TRPM8 (0.57) | TRPM8MEN1KMT2ARAB9AEPHX1 | |
| SCHEMBL14664188 | 0.86 | TRPM8 (0.57) | TRPM8MEN1KMT2ARAB9AEPHX1 | |
| SCHEMBL15133483 | 0.86 | TRPM8 (0.57) | TRPM8MEN1KMT2ARAB9AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656144-B2 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20070053834-A1 | Radioligands for the TRP-M8 receptor and methods therewith | WEI EDWARD T | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070053834-A1 | Radioligands for the TRP-M8 receptor and methods therewith | GPR68, TRPM8, OPRL1 | TRPM8 2/4885TRPV1 10/4885SIGMAR1 287/4885 |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | TSG101, TP53, BAX | TRPM8 28/4885TRPV1 14/4885SIGMAR1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.